Kala's lead product shows promise in two eye indications
This article was originally published in Scrip
The Massachusetts-based ophthalmic company Kala Pharmaceuticals has reported positive data for its formulation of the steroid loteprednol etabonate KPI-121 in two indications, pain in cataract surgery and dry eye disease.
You may also be interested in...
Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.